Pharmos, Bausch & Lomb Pharmaceuticals Inc. deal

PARS finalized its previously announced agreement with Bausch & Lomb to market Lotemax, a site-specific ocular steroidal anti-inflammatory

Read the full 184 word article

How to gain access

Continue reading with a
two-week free trial.